Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 19, 2004
- FY2004 Is Critical for Restoring Good Financial Results: Mr Miyatake of Dainippon
July 19, 2004
- Takara Bio Supplies RetroNectin to NCI of the US for Gene Therapy Trial
July 19, 2004
- MEDICAL DEVICE NEWS IN BRIEF
July 19, 2004
- JGA to Hold 1st Scientific Meeting in Jan. 2005
July 19, 2004
- FPMAJ, EPMA Call For Twice-a-year Listing for Generics
July 19, 2004
- Dr Kodama Stresses Advantage of PTX3 as Marker of Arteriosclerosis: CMIC Seminar
July 19, 2004
- BUSINESS NEWS IN BRIEF
July 19, 2004
- Response Rates to Newest Antidepressants Reach 50-70%: JSMD Symposium
July 19, 2004
- WEBSITE NEWS
July 19, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
July 19, 2004
- Annual Business Results
July 19, 2004
- OTC NEWS IN BRIEF
July 19, 2004
- NEW PRODUCTS
July 19, 2004
- DIAGNOSTIC NEWS IN BRIEF
July 19, 2004
- Levitra Sales See Unexpected Growth: Mr Eiki of Bayer Yakuhin
July 19, 2004
- Mevalotin Retains Top Ranking Despite GE Competition
July 19, 2004
- 380 New Generics, 124 Active Ingredients Added to NHI Price List
July 19, 2004
- Korosho to Announce GVP Ordinance in Near Future
July 19, 2004
- Mr Asonuma of PFSB Discusses Health Policies with EU Officials
July 19, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…